1. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodelling. The role of aldosterone. J Mol Cell Cardiology 2002; 346 1577–84.
2. Guichard JL, Clark D 3rd, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013; 9: 321–31.
3. Lemarie CA, Paradis P, Schiffrin EL. New insights on signalling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008; 86: 673–8.
4. Funder JW. Minireview: aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinology 2010; 151: 5098–102.
5. Junick PC, Lewis SY, Brody MY. Role of central mineralocorticoid binding sites in development of hypertension. Amer J Physiology 1990; 259: 1025–34.
6. Muller J. Regulation of aldosterone biosynthesis: physiological and clinical aspects. Monographs on Endocrinology. 2nd ed. N.Y.: Springer-Verlag, 1988; р. 29.
7. Weber KT, Brilla CG. Myocardial fibrosis and the renin-angiotensin-aldosterone system. J Cardovasc Pharmacology 1992; 20: 48–54.
8. Brilla CG, Zhou G, Weber KT. Aldosterone-mediated stimulation of collagen synthesis in cultured cardiac fibroblasts. J Hypertension 1992; 10: 7.
9. Brown N.J. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005; 14(3): 235–41.
10. Лапшина Л.А. Гипертрофия миокарда левого желудочка при пограничной и мягкой артериальной гипертонии. Експеримент. і клін. мед. 1999; 4: 38–40.
11. Парфенова Е.В., Дьяконова Е.Г., Масенко В.П. и др. Содержание в крови гормонов, нейромедиаторов и гипертрофия левого желудочка у больных гипертонической болезнью. Кардиология. 1995; 7: 18–23.
12. Schunkert H, Hense HW, Muscholl M. et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 1997; 77: 24–31.
13. Минушкина Л.О., Затейщикова А.А., Хотченкова Н.В. и др. Активность ренин-альдостероновой системы и особенности структуры и функции миокарда левого желудочка у больных артериальной гипертонией. Кардиология. 2000; 9: 23–6.
14. Denolle T, Chatellier G, Julien J et al. Left ventricular mass and geometry before and after treatment in renovascular hypertension, aldosterone producing adenoma, and pheochromocytoma. Amer J Hypertension 1993; 6: 907–13.
15. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994; 24: 571–5.
16. Cody RJ. The sympathetic nervous system and the rennin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol 1997; 80 (9B): 9J–14J.
17. Бражник В.А., Затейщиков Д.А., Сидоренко Б.А. Наследственные факторы и гипертрофия левого желудочка. Кардиология. 2003; 1: 78–88.
18. Stas S, Whaley-Connell A, Habibi J et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.Endocrinology 2007; 148 (8): 3773–80.
19. Lastra G, Whaley-Connell A, Manrique C et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008; 295 (1): E110–6.
20. Bochud M, Nussberger J, Bovet P et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006; 48 (2): 239–45.
21. Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension 2010; 55 (4): 813–8.
22. Mosso L, Carvajal C, Gonzalez A et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161–5.
23. Rossi GP, Di Bello V, Ganzaroli C et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002; 40: 23–7.
24. Muiesan ML, Salvetti M, Paini A et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529–34.
25. Milliez P, Girerd X, Plouin PF et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243–8.
26. Catena C, Colussi G, Nadalini E et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80–5.
27. Born-Frontsberg E, Reincke M, Rump LC et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry. J Clin Endocrinol Metab 2009; 94: 1125–30.
28. Catena C. Colussi G, Lapenna R et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911–18.
29. Catena C, Colussi G, Di Fabio A et al. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Horm Metab Res 2010; 42: 440–5.
30. Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33–41.
31. Rossi GP, Bernini G, Caliumi C et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293–300.
32. Calhoun DA, Nishizaka MK, Zaman MA et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892–6.
33. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131 (2):453–9.
34. Jeunemaitre X, Chatellier G, Kreft-Jais C et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820–5.
35. Gallay BJ, Ahmad S, Xu L et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699–705.
36. Strauch B, Zelinka T, Hampf M et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17: 349–52.
37. Eide IK, Torjesen PA, Drolsum A et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22: 2217–26.
38. Мареев В.Ю., Скорцов А.А., Челмакина С.М. и др. Способны ли ингибиторы ангиотензинпревращающего фермента эффективно контролировать активность ренин-ангиотензин-альдостероновой системы при длительном лечении хронической сердечной недостаточности? Кардиология. 1999; 2: 27–34.
39. Шляхто Е.В. Нейрогуморальные модуляторы в лечении хронической сердечной недостаточности. Сердечная недостаточность. 2001; 1: 134–41.
40. Dahlstrom U, Karlsson E. Captopril and spironolactone therapy in patients with refractory congestive heart failur. Curr Ther Res 1992; 51: 235–48.
41. Jessup M. Aldosterone blockade and heart failure. New Engl J Med 2003; 348: 1380–2.
42. Pitt B., Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 2003; 348: 1309–21.
43. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168: 1159–64.
44. Mohammed SF, Ohtani T, Korinek J et al. Mineralocorticoid accel- erates transition to heart failure with preserved ejection fraction via «nongenomic effects». Circulation 2010; 122: 370–8.
45. Young MJ, Lam EY, Rickard AJ. Mineralocorticoid receprtor activator and cardiac fibrosis. Clin Sci (Lond.) 2007; 112 (9): 467–75.
46. Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs 1991; 41 (Suppl. 3): 80–91.
47. Baumgart P, Walger P, von Eiff M, Achhammer I. Long-term efficacy and tolerance of torasemide in hypertension. Prog Pharmacol Clin Pharmacol 1990; 8: 169–81.
48. Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther 1993; 7 (Suppl. 1): 63–8.
49. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the hypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittelforschung 1988; 38 (1A): 190–3.
50. Reyes AJ, Chiesa PD, Santucci MR et al. Hydrochlorothiazide versus a non-diuretic dose of torasemide as once-daily antihypertensive monopharmacotherapy in elderly patients. A randomized and double-blind study. Prog Pharmacol Clin Pharmacol 1990; 8 (1): 183–209.
51. Achhammer I, Eberhard R. Comparison of serum potassium levels during long-term treatment of hypertensive patients with 2.5 mg torasemide/day or 50 mg triamterene/25 mg hydrochlorothiazide/day. Prog Pharmacol Clin Pharmacol 1990; 8 (Issue 1): 211–20.
52. Cosin J, Diez J. On behalf of the TORIC investigators. Torasemide in chronic heart failure: results of the TORIC. Eur J Heart Fail 2002; 4 (4): 507–13.
53. Knauf H, Mutschler E, Velazquez H, Giebisch G. Torasemide significantly reduces thiazide-induced porassium and magnesium loss despite supraadditive natriuresis. Eur J Clin Pharmacol 2009; 65 (5): 465–72.
54. Harada K, Izawa H, Nishizawa T et al. Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol 2009; 53 (6): 468–73.
55. Goodfriend TL, Ball DL, Oelkers W, Bähr V. Torsemide inhibits aldosterone secretion in vitro. Life Sc 1998; 63 (3): 45–50.
56. Franse LV, Pahor M, Di Bari M et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35 (5): 1025–30.
57. Lopez B, Querejeta R, Gonzales A et al. Effects of loop diuretics on myocardial fibrosis and collage type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43 (11): 2028–35.
58. Аверин Е.Е. Влияние торасемида на гипертрофию миокарда левого желудочка. Сердечная недостаточность. 2012; 13 (3): 158–61.
59. Sever PS, Dahlof B, Poulter NR et al. For the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366 (9489): 895–906.
60. Massare J, Berry JM, Luo X et al. Diminished cardiac fibrosis in heart failure is associated with altered ventricular arrhythmia phenotype. J Cardiovasc Electrophysiol 2010; 21 (9): 1031–7.
61. Brown NJ. Aldosterone and end–organ damage. Curr Opin Nephrol Hypertens 2005; 14 (3): 235–41.
62. Reyes AJ, Leary WP, Van Der Byl K. Renal excretory responses to single and repeated administration of loop and of early distal tubular diuretics at various doses in healthy man. Prog Pharmacol Clin Pharmacol 1992; 9: 219–62.
63. Liguori A, Casini A, Di Loreto M et al. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure. Eur J Clin Pharmacol 1999; 55 (2): 117–24.
64. Spieker C, Zidek W, Häcker W et al. Assessment of intracellular sodium and calcium in essential hypertension during diuretic treatment. Arzneimittelforschung 1988; 38 (1А): 1188–90.
65. Кутырина И.М., Крячкова А.А., Савельева С.А., Шестакова М.В. Роль альдостерона в поражении почек при метаболическом синдроме, ассоциированном с ожирением. Клин. нефрология. 2010; 4: 34–44.

Г.А.Барышникова1, Е.Е.Аверин2

1. Кафедра семейной медицины УНМЦ Управления делами Президента РФ, Москва
2. Кафедра кардиологии ФУВ ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФ; ООО «Тева», Россия